• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Health

UCLA Health
  • About Us
    • What is UCLA Health?
    • Contact Us
    • Your Feedback
    • Accountable Care Organization
    • Awards & Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • In the Community
    • 340B Program
    • Industry Relations
    • Innovation
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    Vital SignsLinked Graphic: Subscribe to Health Newsletters
    • Contact
    • Your Feedback
    • Accountable Care Organization
    • Awards and Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • Industry Relations
    • Innovation
    • In the Community
    • 340B Program
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    • Subscribe to UCLA Health Newsletters
  • Conditions & Treatment
    • Health Library
    • Tests & Procedures
    • Drug Interaction Checker
    • Brain & Nervous System
    • Cancer
    • Children's Health
    • Heart Disease
    • Nutrition & Wellness
    • Pregnancy & Newborns
    • Orthopedics
    • Women's Health
    • Video Library
    • Cancer
    • Cardiovascular
    • Chiropractic
    • Cosmetic Surgery
    • Ear, Nose and Throat
    • Gastrointestinal
    • General Healthcare
    • Neurological
    • Obstetrics/Gynecology
    • See all videos...
    Symptom Checker
    • Video Library
  • Locations

    Hospitals

    • Ronald Reagan UCLA Medical Center
    • UCLA Medical Center, Santa Monica
    • UCLA Mattel Children's Hospital
    • Resnick Neuropsychiatric Hospital
    • Institutes and Centers
    • Take a Virtual Tour

    Medical Offices/Clinics

    • Primary Care
    • Specialty Care
    • Urgent Care Centers
    • Outpatient Surgery Centers
    • Community Cancer Care
    • Imaging/Radiology Locations
    • Clinical Labs
    • Pharmacies

    Interactive Map

    interactive map

    • Locations Coming Soon
    • UCLA Hospitals
    • Take a Virtual Tour
    • Primary Care Practices
    • Specialty Care Practices
    • Urgent Care Centers
    • Outpatient Surgery Centers
    • Other Locations
    • Interactive Map
    • Coming Soon!
  • Medical Services
  • For Patients & Visitors
    • Directions & Parking
    • Appointments: Call, Click, Come In
    • Admissions Information
    • Preparing For Surgery
    • Patient Services
    • Security & Parking Services
    • Office of the Patient Experience
    • For International Patients
    • Lodging & Nearby Services
    • Around Westwood
    • Gift Shops & Flowers
    • Health Resources
    • Log in to myUCLAhealth
    • About myUCLAhealth
    • Billing Information
    • Medical Records
    • Accountable Care Organization (ACO)
    • Covered California
    • Health Plans
    • Price Transparency
    • Interactive Patient Education Videos (Emmi)
    • FAQs
    • Calendar of Events
    • Secure Email Messages
    • Share your story. Connect. Share. Improve. UCLA Health
    • Share Your Story
    • Health Publications
    • Vital Signs Newsletters
    • Health Tips for Parents
    • Contact Us
    • Appointments: Call, Click, Come in
    • Admissions Information
    • Advance Directive
    • Directions & Parking
    • Patient Services
    • Medical Records
    • myUCLAhealth
    • Smoke-Free
    • Publications
    • Health Resources
    • Around Westwood
    • Lodging
    • Preparing For Surgery
    • Patient-focused Technology Council
    • Health Forms
    • End of Life Option Act: Resources & Materials
    • Frequently Asked Questions
    • Secure Email Messages
    • Gift Shops
  • For Healthcare Professionals
    • Referring a Patient
    • Continuing Medical Education
    • Ethics Center
    • UCLA HealthLink
    • Physician to Physician Access Line (P2P)
    • David Geffen School of Medicine at UCLA
    • Clinical Informatics Fellowship
    • Academic Positions
    • Physician Careers
    • UCLA School of Dentistry
    • UCLA School of Nursing
    • Department of Nursing

    Physician Publications

    • Physicians Update
    • Clinical Updates
    • U Magazine
    • Physician to Physician Access Line (P2P)
    • Physician Careers
    • Clinical Informatics Fellowship
    • Flu Resources for Healthcare Professionals
    • Publications
  • Multimedia
    • UCLAMDCHAT Webinars
    • Community Health Program Videos
    • iTunes
    • Download Our Apps
    • Mini Med School
    • Demystifying Cancer Forum
    • TEDx UCLA Videos
    • Tips from our Physical Therapists
    • Patient Stories
    • Real Questions
    • Webinars on Demand
    • Pediatric Grand Rounds
    • Tune in to watch our health webinars
    • Community Health Program Videos
    • UCLAMDChat Webinars
    • iTunes
    • Download Our Apps
    • Mini Med School
    • Demystifying Cancer Forum
    • TEDx UCLA Videos
    • Tips From Our Physical Therapists
    • Patient Stories
    • Real Questions
    • Back Pain Management
  • Find a Provider
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

About Us

About Us

About Us

  • Contact
  • Your Feedback
  • Accountable Care Organization
    • ACO - Anthem Blue Cross PPO
      • Anthem Blue Cross PPO ACO FAQ
  • Awards and Achievements
    • UCLA Health hospitals again rank No. 1 in Los Angeles, No. 7 nationally
    • UCLA Designated a National Magnet Hospital
  • Careers
  • Careers for Physicians
  • Departments - Administrative
  • Departments - Clinical
  • Giving to UCLA Health
  • Industry Relations
  • Innovation
  • In the Community
    • Community Health
  • 340B Program
  • Leadership
    • Dr. John Mazziotta
    • Johnese Spisso
    • Dr. Kelsey Martin
  • News Releases
  • Price Transparency
  • Social Media
  • Subscribe to UCLA Health Newsletters
  • Contact
  • Your Feedback
  • Accountable Care Organization
  • Awards and Achievements
  • Careers
  • Careers for Physicians
  • Departments - Administrative
  • Departments - Clinical
  • Giving to UCLA Health
  • Industry Relations
  • Innovation
  • In the Community
  • 340B Program
  • Leadership
  • News Releases
  • Price Transparency
  • Social Media
  • Subscribe to UCLA Health Newsletters
  1. Home
  2. About Us
  3. News Releases

News Releases

Share this

Health and Behavior

How a small molecule halts the spread of a toxic protein associated with Alzheimer’s progression

UCLA research could help lead to design of drugs that slow neurodegeneration

05/02/2018

Kanagasabai Vadivel/UCLA Drug Discovery Lab
nSMAse2 joins cambinol

Alzheimer’s disease destroys brain cells in part by promoting the formation of insoluble clumps that contain a protein called tau. Not only are these “tau aggregates” toxic for the cells that harbor them, but they also invade and destroy neighboring brain cells, or neurons, which speeds the cognitive decline associated with the Alzheimer’s.

For those reasons, Alzheimer’s researchers have been intensely interested in therapies aimed at either preventing tau aggregation or blocking its spread.

Now, researchers at the UCLA School of Nursing and the department of neurology at the David Geffen School of Medicine at UCLA have reported a promising drug strategy that blocks tau transmission. The study was published online in the journal Biochemical and Biophysical Research Communications.

Using cultured cells, mouse models and protein structural analysis, the researchers found that a small molecule called cambinol blocks the transfer of tau aggregates from cell to cell. The study could help lay the groundwork for therapies to treat Alzheimer’s or other dementias associated with the accumulation of tau.

“Over 200 molecules have been tested as disease-modifying Alzheimer’s therapy in clinical trials, and none has yet attained the holy grail,” said Varghese John, a UCLA associate professor of neurology and the study’s senior author. “Our paper describes a novel approach to slow Alzheimer’s progression by showing it is possible to inhibit propagation of pathologic forms of tau.”

Varghese John

John is a member of the UCLA Easton Center for Alzheimer’s Disease Research and leads the Drug Discovery and Translational lab.

In healthy people, tau proteins are benign building blocks of a neuron’s framework, or cytoskeleton. But in Alzheimer’s disease, tau proteins fall away from the cytoskeleton, become abnormally modified, and then form insoluble “neurofibrillary tangles” that destroy cells. To make matters worse, dying cells encase tau aggregates in lipid vesicles called exosomes, which then bud off and “seed” neighboring tissues, keeping the destructive cycle going.

The researchers conducted several experiments that suggest that cambinol can subvert the “transfer” step by blocking an enzyme called nSMase2, which is essential for catalyzing production of the exosome carriers. In one, the scientists used “donor cells” that harbored tau aggregates derived from postmortem human Alzheimer’s specimens and mixed them with tau-free recipient cells.

Without cambinol, the aggregates spread from donors to recipients, mirroring what happens in the brains of people with Alzheimer’s. But when treated with cambinol, recipient cells remained tau-free when grown side by side with tau-positive donors, presumably because the drug disabled nSMase2 activity blocking release of the tau-carrying exosomes.

The researchers also observed decreased nSMase2 catalytic activity in the brains of mice that were given cambinol orally. John said the seemingly routine experiment was an essential first step.

“Getting molecules into the brain is a big hurdle, because most drugs don’t penetrate the blood-brain barrier,” he said, referring to the membranes that surround the central nervous system and keep drugs out of it. “Now we know we can treat animals with cambinol to determine its effect on Alzheimer’s pathology and progression.”

The paper is the first to report on a model of how cambinol switches off nSMase2 catalytic activity at the atomic level, and it provides critical knowledge for medicinal chemists like John to begin designing new drugs based on cambinol that are more potent and efficacious than the molecule itself. That work is already being done in collaboration with Neil Garg, a UCLA professor of chemistry and biochemistry. If the approach is successful in animals, it could be tested in clinical trials.

UCLA School of Nursing
Karen Gylys

“Understanding pathways is the first step to new drug targets,” said Karen Gylys, a UCLA professor of nursing and a co-author of the study. “With cambinol in hand, we have a useful tool for understanding cellular pathways that enable the spread of tau pathology.”

UCLA’s Tina Bilousova is the study’s lead author. Other authors, all of UCLA, are Chris Elias, Emily Miyoshi, Mohammad-Parvez Alam, Chunni Zhu, Jesus Campagna, Kanagasabai Vadivel and Barbara Jagodzinska.

The study was supported by grants from the National Institute of Aging and the UCLA Department of Neurology. 



Media Contact
Laura Perry
310-794-4022
lperry@sonnet.ucla.edu



Latest News

Health and Behavior
Sexually transmitted infections are on the rise. Here’s what you need to know to protect yourself
02/14/2019
In a Q&A, UCLA’s Dr. Leena Nathan explains which infections sexually active people are more likely to be exposed to and to contract.

Health and Behavior
Electrical activity early in fruit flies’ brain development could shed light on how neurons wire the brain
02/12/2019
A study by UCLA neuroscientists suggests that the signals could help neurons find each other to form networks.

Health and Behavior
For recurrent glioblastoma, immunotherapy before surgery appears to help more than afterward
02/11/2019
“We now have a rational and logical way to develop immunotherapies going forward and a clinical development process for doing it,” said UCLA's Dr. Timothy Cloughesy.

Health and Behavior
Music therapy program at UCLA aims to help premature infants develop feeding skills
02/11/2019
Researchers worked with a family with triplets to study a lullaby device used in the intensive care unit.

Health and Behavior
Shorter course of radiation therapy effective in treating men with prostate cancer
02/08/2019
A long-term, UCLA-led study finds that those with low- or intermediate-risk disease can safely cut treatment to four to five days.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest Follow us on Flickr Follow us on Sharecare
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-800-UCLA-MD1
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest Follow us on Flickr Follow us on Sharecare

Sign in to myUCLAhealth